(UroToday.com) The Society of Urologic Oncology (SUO) annual winter meeting included a prostate cancer session and a presentation by Dr. Gerald Andriole discussing the impact of 18F-fluciclovine PET/CT on plans for ADT in patients with biochemical recurrence of prostate cancer. Despite improvements in early detection and primary therapy, biochemical recurrence of prostate cancer after curative-intent primary therapy remains common. The advent of highly sensitive molecular imaging has allowed the identification of men with limited metastatic disease burden that might be more optimally treated with metastases-directed therapy rather than with systemic therapy. The LOCATE1 and FALCON2 trials assessed the impact of 18F-fluciclovine PET/CT on the management of patients with prostate cancer recurrence after curative-intent primary therapy. Thus, the objective of this study was to analyze data from LOCATE and FALCON to evaluate the impact of 18F-fluciclovine on plans for ADT in patients with biochemical recurrence of prostate cancer.